Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Rhythm Pharmaceuticals (NASDAQ:RYTM) Full Year 2024 Results

Key Financial Results

• Revenue: US$130.1m (up 68% from FY 2023).
• Net loss: US$264.6m (loss widened by 43% from FY 2023).
• US$4.34 loss per share (further deteriorated from US$3.20 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rhythm Pharmaceuticals Revenues Beat Expectations

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) was mostly in line with analyst estimates.

In the last 12 months, the only revenue segment was Development and Commercialization of Therapies for Patients with Rare Diseases contributing US$130.1m. The largest operating expense was Research & Development (R&D) costs, amounting to US$238.0m (62% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$931.0k. Explore how RYTM's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Rhythm Pharmaceuticals' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.